Inclusion criteria | 1. Kidney transplantation >6 weeks and <12 months before randomization |
2. Age ≥18 years | |
3. Presence of an acute T-cell mediated tubulointerstitial rejection (Banff IA or IB) or Banff borderline rejection with simultaneous serum creatinine increase of ≥20% over baseline | |
4. Significant numbers of B-cell infiltrates (defined as >30 CD20+cells /hpf) | |
5. Absence of C4d and SV40 | |
6. Creatinine clearance >25 ml/min. | |
7. Reliable contraception | |
8. Written informed consent | |
Exclusion criteria | 1. Known adverse reactions against rituximab or concomitant medication |
2. Application of rituximab for any reason 12 months prior inclusion | |
3. Women who are pregnant or breastfeeding | |
4. Active CMV, HIV, replicative Hepatitis B or C, or other relevant infections | |
5. Splenectomy | |
6. Heart insufficiency (NYHA III-IV) | |
7. Severe arrhythmia | |
8. Insufficiently controlled diabetes mellitus (HbA1c >10 %) | |
9. Contraindication for a second transplant biopsy (for example, coagulation disorders) | |
10. Other reasons according to the assessments of the study physician |